Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amiodarone and post-MI patients

K Nademanee1, B N Singh, W G Stevenson

  • 1Department of Cardiology, Denver (Colo) General Hospital 80204.

Circulation
|August 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mechanistic and recent updates in nano-bioremediation for developing green technology to alleviate agricultural contaminants.

International journal of environmental science and technology : IJEST·2022
Same author

A machine learning-based approach to determine infection status in recipients of BBV152 (Covaxin) whole-virion inactivated SARS-CoV-2 vaccine for serological surveys.

Computers in biology and medicine·2022
Same author

How is Biodegradable Scaffold Effective in Gap Non-union? Insights from an Experiment.

Indian journal of orthopaedics·2021
Same author

Computational exploration and anti-mycobacterial activity of potential inhibitors of <i>Mycobacterium tuberculosis</i> acetyl coenzyme A carboxylase as anti-tubercular agents.

SAR and QSAR in environmental research·2021
Same author

Fabrication and evaluation of non-mulberry silk fibroin fiber reinforced chitosan based porous composite scaffold for cartilage tissue engineering.

Tissue & cell·2018
Same author

Studies on effect of CuO addition on mechanical properties and in vitro cytocompatibility in 1393 bioactive glass scaffold.

Materials science & engineering. C, Materials for biological applications·2018
Same journal

Deprescribing in Patients With Cardiovascular Disease Experiencing Polypharmacy: A Scientific Statement From the American Heart Association.

Circulation·2026
Same journal

A Bundle to Frame Guidelines and American Heart Association Statements.

Circulation·2026
Same journal

<i>Circulation</i> Editors and Editorial Board.

Circulation·2026
Same journal

A New <i>Circulation</i>, For You.

Circulation·2026
Same journal

Cardiovascular Risk Reduction With GLP-1 RA Drugs.

Circulation·2026
Same journal

Obesity, Severe Obesity, and Abdominal Obesity in US Youth and Adults From 1999 to 2023.

Circulation·2026
See all related articles

Amiodarone effectively prevents sudden cardiac death in the first year after myocardial infarction (MI). Further trials are needed to confirm its benefits outweigh risks, especially in high-risk patients.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Sudden cardiac death (SCD) remains a significant risk post-myocardial infarction (MI).
  • Current treatments like ACE inhibitors show delayed benefits, not impacting early post-MI mortality.
  • Amiodarone presents a potential early intervention for SCD prevention.

Purpose of the Study:

  • To evaluate the efficacy of amiodarone in preventing sudden cardiac death in the crucial first year after myocardial infarction.
  • To compare amiodarone's risk-benefit profile with existing therapies and explore optimal treatment durations and combinations.

Main Methods:

  • Review of prospective trials (Ceremuzynski et al, Cairns et al, BASIS trial) and large-scale studies (SAVE, CONSENSUS II, SOLVD).
  • Analysis of amiodarone's antiarrhythmic properties and effects on ventricular function.

Related Experiment Videos

  • Identification of areas for further research, including combination therapies and specific patient subgroups.

    • Main Results:

    • Amiodarone demonstrates efficacy in preventing SCD within the first year post-MI.
    • Unlike other antiarrhythmics, amiodarone does not negatively impact ventricular function.
    • Long-term data suggests a 1-year treatment duration may be optimal for post-MI patients.

    Conclusions:

    • Amiodarone is a viable option for early SCD prevention after MI, with benefits potentially outweighing risks.
    • Further research is warranted to optimize amiodarone therapy, including combination with other drugs and its use in specific high-risk populations.
    • Understanding amiodarone's molecular mechanisms is crucial for enhancing its therapeutic application.